Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) issued its quarterly earnings results on Monday. The pharmaceutical company reported $4.47 EPS for the quarter, beating analysts’ consensus estimates of $4.23 by $0.24, FiscalAI reports. The firm had revenue of $2.99 billion for the quarter, compared to analysts’ expectations of $2.99 billion. Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.
Here are the key takeaways from Vertex Pharmaceuticals’ conference call:
- Vertex reported strong Q1 results with $2.99 billion in product revenue (+8% YoY), reiterated full‑year guidance of $12.95–13.1 billion, ended Q1 with ~$13 billion in cash, and continued share repurchases — supporting near‑term financial momentum.
- Pivotal RAINIER interim Phase III data for povetacicept (Povi) in IgAN were described as “sparkling” — a 52% proteinuria reduction vs baseline (≈49.8% vs placebo), favorable safety, a 27‑day BLA filing turnaround, and initiation/advancement of PMN and gMG programs, underpinning a new renal franchise opportunity.
- Commercial momentum outside CF: CASGEVY has >500 patients initiated and delivered $43M in Q1 while securing reimbursement progress (e.g., Germany), and JOURNAVX surpassed 1M prescriptions written with 350k scripts in Q1 and expanded payer coverage (≈240M lives), supporting the company’s goal of >$500M non‑CF revenue in 2026.
- CF franchise remains core: ALYFTREK exceeded $1 billion cumulative revenue and recent label expansions for ALYFTREK/TRIKAFTA extend eligibility to ~95% of people with CF; next‑gen modulators (VX‑828, VX‑581, VX‑272) are progressing with a VX‑828 patient readout expected H2 2026.
- Vertex discontinued the VX‑522 mRNA program for patients who produce no CFTR protein due to lung inflammatory/tolerability issues, meaning the company will not advance this delivery approach for the hardest‑to‑treat CF patients and must pursue alternative modalities.
Vertex Pharmaceuticals Stock Performance
Vertex Pharmaceuticals stock traded up $5.93 during midday trading on Monday, reaching $429.85. 1,418,049 shares of the stock were exchanged, compared to its average volume of 1,394,366. Vertex Pharmaceuticals has a 52 week low of $362.50 and a 52 week high of $507.92. The firm has a market cap of $109.34 billion, a PE ratio of 28.04, a PEG ratio of 1.84 and a beta of 0.30. The company’s fifty day moving average is $453.82 and its 200-day moving average is $449.48.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on Vertex Pharmaceuticals
Insider Activity
In other news, EVP Jonathan Biller sold 1,925 shares of the company’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $460.43, for a total value of $886,327.75. Following the transaction, the executive vice president owned 20,819 shares of the company’s stock, valued at approximately $9,585,692.17. This represents a 8.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Mark E. Bunnage sold 2,021 shares of the stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total value of $930,529.03. Following the completion of the sale, the executive vice president owned 12,914 shares in the company, valued at $5,945,993.02. This trade represents a 13.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 80,431 shares of company stock worth $37,875,167. Company insiders own 0.20% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. Motiv8 Investments LLC bought a new position in shares of Vertex Pharmaceuticals in the fourth quarter worth approximately $26,000. Swiss RE Ltd. bought a new stake in Vertex Pharmaceuticals during the fourth quarter valued at approximately $28,000. Sfam LLC purchased a new position in Vertex Pharmaceuticals in the 4th quarter worth approximately $45,000. Kelleher Financial Advisors bought a new position in shares of Vertex Pharmaceuticals in the 3rd quarter worth $39,000. Finally, Kemnay Advisory Services Inc. bought a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth $46,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.
More Vertex Pharmaceuticals News
Here are the key news stories impacting Vertex Pharmaceuticals this week:
- Positive Sentiment: Adjusted profit and EPS beat expectations — Vertex reported quarterly EPS that topped Street estimates and strong profitability metrics, supporting near‑term earnings confidence. Vertex Reports First Quarter 2026 Financial Results
- Positive Sentiment: Sales of a new cystic fibrosis drug surged — reports note a near eight‑fold increase in sales of Vertex’s new CF treatment, a key growth driver that helped lift revenue and investor sentiment. Vertex tops profit estimates as sales of new cystic fibrosis drug surge
- Positive Sentiment: Regulatory expansion strengthens the CF franchise — FDA expanded use of ALYFTREK for younger CF patients, broadening the addressable market for Vertex’s core cash‑generating franchise. How Investors Are Reacting To Vertex (VRTX) FDA ALYFTREK Expansion and Evolving Pipeline Story
- Positive Sentiment: Underlying profitability and income grew YoY — operating profit and net income showed strong year‑over‑year increases, reinforcing the company’s cash‑flow generation profile. Vertex Pharmaceuticals (VRTX) Stock Falls on Q1 2026 Earnings
- Neutral Sentiment: FY‑2026 revenue guidance reiterated and essentially in line with consensus — management maintained revenue guidance of roughly $13.0–$13.1B, removing some uncertainty but not materially surprising investors. View Press Release
- Neutral Sentiment: Analyst coverage remains broadly positive but targets vary widely — many buy/outperform ratings remain and median targets are well above the current price, suggesting continued long‑term bullishness despite near‑term dispersion. Vertex Pharmaceuticals (VRTX) Stock Falls on Q1 2026 Earnings
- Negative Sentiment: Some third‑party data feeds showed mixed/missed metrics — a published data set reported diluted EPS and revenue below certain consensus figures, which prompted short‑term after‑hours weakness in some quotes. Vertex Pharmaceuticals (VRTX) Stock Falls on Q1 2026 Earnings
- Negative Sentiment: Material insider selling and some institutional reductions — reporting shows significant insider dispositions and large institutional rebalances, which can weigh on near‑term sentiment. Vertex Pharmaceuticals (VRTX) Stock Falls on Q1 2026 Earnings
- Negative Sentiment: Some cash‑flow and balance sheet items need watching — operating cash from activities was reported lower YoY and capex rose, while total liabilities increased, factors investors may monitor for cash conversion and reinvestment. Vertex Pharmaceuticals (VRTX) Stock Falls on Q1 2026 Earnings
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.
Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.
Featured Stories
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
